A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
NCT07578571
·
clinicaltrials.gov ↗
PHASE1
Phase
NOT_YET_RECRUITING
Status
175
Enrollment
INDUSTRY
Sponsor class
Conditions
Colorectal Cancer
Non-Small Cell Lung Cancer
Breast Cancer
Esophageal Cancer
Stomach Cancer
Cancer
Interventions
DRUG:
IM-1617
Sponsor
Immunome, Inc.